Australia Oligonucleotide Synthesis Market Size & Outlook
Australia oligonucleotide synthesis market, 2018-2030 (US$M)
Related Markets
Australia oligonucleotide synthesis market highlights
- The Australia oligonucleotide synthesis market generated a revenue of USD 67.1 million in 2024 and is expected to reach USD 128.8 million by 2030.
- The Australia market is expected to grow at a CAGR of 11.5% from 2025 to 2030.
- In terms of segment, services was the largest revenue generating segment in 2024.
- Services is the most lucrative segment segment registering the fastest growth during the forecast period.
Oligonucleotide synthesis market data book summary
| Market revenue in 2024 | USD 67.1 million |
| Market revenue in 2030 | USD 128.8 million |
| Growth rate | 11.5% (CAGR from 2024 to 2030) |
| Largest segment | Services |
| Fastest growing segment | Services |
| Historical data | 2018 - 2023 |
| Base year | 2024 |
| Forecast period | 2025 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Oligonucleotides, Equipment/Synthesizer, Reagents, Services |
| Key market players worldwide | Thermo Fisher Scientific Inc, Merck KGaA, GE HealthCare Technologies Inc Common Stock, Agilent Technologies, Kaneka Corp, Heritage Global Inc, Twist Bioscience Corp, Bio-Synthesis, Biolegio |
Other key industry trends
- In terms of revenue, Australia accounted for 1.7% of the global oligonucleotide synthesis market in 2024.
- Country-wise, U.S. is expected to lead the global market in terms of revenue in 2030.
- In Asia Pacific, China oligonucleotide synthesis market is projected to lead the regional market in terms of revenue in 2030.
- China is the fastest growing regional market in Asia Pacific and is projected to reach USD 868.4 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Oligonucleotide Synthesis Market Scope
Oligonucleotide Synthesis Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|
Australia oligonucleotide synthesis market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to oligonucleotide synthesis market will help companies and investors design strategic landscapes.
Services was the largest segment with a revenue share of 37.41% in 2024. Horizon Databook has segmented the Australia oligonucleotide synthesis market based on oligonucleotides, equipment/synthesizer, reagents, services covering the revenue growth of each sub-segment from 2018 to 2030.
Australia has established and emerging players in the oligonucleotide synthesis market, like Genetic Signatures, Starpharma, and Patrys Limited. These companies are actively researching, developing, and commercializing innovative oligonucleotide-based technologies. Australia has strengths in several areas, such as regenerative medicine and gene editing, where oligonucleotides play a crucial role.
Moreover, the government actively supports developing the biotechnology sector, including oligonucleotide technologies. Funding R&D programs, providing tax breaks for innovative companies, and streamlining regulatory processes are some key initiatives.
Reasons to subscribe to Australia oligonucleotide synthesis market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Australia oligonucleotide synthesis market databook
-
Our clientele includes a mix of oligonucleotide synthesis market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of country-level data and insights on the Australia oligonucleotide synthesis market , including forecasts for subscribers. This country databook contains high-level insights into Australia oligonucleotide synthesis market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Partial client list
Australia oligonucleotide synthesis market size, by segment, 2018-2030 (US$M)
Australia Oligonucleotide Synthesis Market Outlook Share, 2024 & 2030 (US$M)
Related regional statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
